H
Harold L. Dauerman
Researcher at University of Vermont Medical Center
Publications - 30
Citations - 1519
Harold L. Dauerman is an academic researcher from University of Vermont Medical Center. The author has contributed to research in topics: Angioplasty & Population. The author has an hindex of 12, co-authored 30 publications receiving 1416 citations. Previous affiliations of Harold L. Dauerman include University of Massachusetts Amherst & Harvard University.
Papers
More filters
Journal ArticleDOI
Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2 Double-Blind, Randomized, Controlled Clinical Trial
Michael Simons,Brian H. Annex,Roger J. Laham,Neal S. Kleiman,Timothy D. Henry,Harold L. Dauerman,James E. Udelson,Ernesto V. Gervino,Marilyn Pike,M. J. Whitehouse,Thomas Moon,Nicolas A. Chronos +11 more
TL;DR: A single intracoronary infusion of rFGF2 does not improve exercise tolerance or myocardial perfusion but does show trends toward symptomatic improvement at 90 (but not 180) days.
Journal ArticleDOI
Twenty-two year (1975 to 1997) trends in the incidence, in-hospital and long-term case fatality rates from initial q-wave and non-q-wave myocardial infarction: a multi-hospital, community-wide perspective
Mark I. Furman,Harold L. Dauerman,Robert J. Goldberg,Jorge Yarzbeski,Darleen M. Lessard,Joel M. Gore +5 more
TL;DR: Despite impressive declines in the incidence, in-hospital and long-term mortality associated with QWMI, NQWMI is increasing in frequency and has the same in- hospital mortality now as it did 22 years ago.
Journal ArticleDOI
Mechanical debulking versus balloon angioplasty for the treatment of diffuse in-stent restenosis.
Harold L. Dauerman,Donald S. Baim,Donald E. Cutlip,Anthony Sparano,C. Michael Gibson,Richard E. Kuntz,Joseph P. Carrozza,Gary R. Garber,David J. Cohen +8 more
TL;DR: The strategy of atherectomy and adjunctive PTCA for diffuse in-stent restenosis is safe, improves acute angiographic results compared with P TCA alone, and may decrease the need for target vessel revascularization.
Journal ArticleDOI
1-Year Results in Patients Undergoing Transcatheter Aortic Valve Replacement With Failed Surgical Bioprostheses
G. Michael Deeb,Stanley Chetcuti,Michael J. Reardon,Himanshu J. Patel,P. Michael Grossman,Theodore Schreiber,John K. Forrest,Tanvir Bajwa,Daniel O'Hair,George Petrossian,Newell Robinson,Stanley Katz,Alan R. Hartman,Harold L. Dauerman,Joseph D. Schmoker,Kamal R. Khabbaz,Daniel R. Watson,Steven J. Yakubov,Jae K. Oh,Shuzhen Li,Neal S. Kleiman,David H. Adams,Jeffrey J. Popma +22 more
TL;DR: Self-expanding TAVR in patients with SVF at increased risk for surgery was associated with a low 1-year mortality and major stroke rate, significantly improved aortic valve hemodynamics, and low rates of moderate and no severe residual aorta regurgitation, with improved quality of life.
Journal ArticleDOI
Mechanical debulking versus balloon angioplasty for the treatment of true bifurcation lesions
Harold L. Dauerman,Peter J. Higgins,Anthony Sparano,C. Michael Gibson,Gary R. Garber,Joseph P. Carrozza,Richard E. Kuntz,Roger J. Laham,Samuel J. Shubrooks,Donald S. Baim,David J. Cohen +10 more
TL;DR: For the treatment of true bifurcation lesions, atherectomy with adjunctive P TCA is safe, improves acute angiographic results, and decreases target vessel revascularization compared to PTCA alone.